Print full article
Currently, there is no cure for fibromyalgia. Few people achieve complete remission of their symptoms, but most learn to live with their condition and are able to live relatively normal lives. Fibromyalgia is not inherently crippling, and it does not decrease the lifespan of those affected by it. Treatment centers on lifestyle changes and symptom relief. Support groups and counselling may help a patient deal with the physical, psychological, financial, and social frustrations their condition can cause.
A gentle exercise program is strongly recommended, as it is one of the few measures shown to be of benefit. Regular aerobic exercise and stretching can help maintain muscle conditioning, improve sleep, and decrease pain and stiffness. Caution should be used, especially when starting to exercise, as overexertion can cause painful flare-ups. Stress reduction and limiting caffeine and alcohol also may help to reduce symptoms.
Drug therapies may be able to offer at least short-term symptom improvement, including decreased pain and increased quality of sleep. Tricyclic antidepressants have proven useful for some patients, not because of depression but because of the way the treatment affects brain chemistry. The first U.S. Food and Drug Administration approved treatment, as of June 2007, is the drug pregabalin, an anticonvulsant. Patients with fibromyalgia should work with their doctors to determine the best course of treatment for them. What works for one person may not work for another, and many people with fibromyalgia are especially sensitive to medication side-effects.
Pregabalin is available in Australia, but is not funded on the as yet for this indication. Many medications used in the treatment of fibromyalgia lead to excess sedation.
Patients with fibromyalgia should work with their doctors to determine the best course of treatment for them. What works for one person may not work for another, and many people with fibromyalgia are especially sensitive to medication side-effects.
Last Review Date: April 1, 2018